India, July 30 -- Shares of Nuwellis, Inc. (NUWE) are surging about 133 percent on Thursday morning after Frontiers in Pediatrics accepted publication of a new single-center retrospective study evaluating Epoprostenol as an alternative anticoagulant for its Aquadex ultrafiltration therapy in critically ill children.
The company's shares are currently trading at $4.40 on the Naasdaq, up 133.33 percent. The stock opened at $5.14 and has climbed as high as $6.3999 so far in today's session. Over the past year, it has traded in a range of $1.83 to $378.35.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....